Citigroup
SKYE icon

Citigroup’s Skye Bioscience SKYE Stock Holding History

Citigroup’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– -$1 – 6327
2026
Q1 		– Hold
0
– – – 5881
2025
Q4 		– Hold
0
– -$4 – 6557
2025
Q3 		– Hold
0
– – – 5998
2025
Q2 		– Sell
-1,748
Closed -$22.2K – 5945
2025
Q1 		$22.2K Sell
1,748
-160
-8% -$3.49K ﹤0.01% 5066
2024
Q4 		$43.2K Buy
1,908
+342
+22% +$11.4K ﹤0.01% 5123
2024
Q3 		$49K Buy
1,566
+1,085
+226% +$48.7K ﹤0.01% 5026
2024
Q2 		$30.8K Buy
+481
New +$45.7K ﹤0.01% 4852

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citigroup's SKYE Position: Q2 2026 in Review

Citigroup held its Skye Bioscience (SKYE) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6327.

Citigroup first reported a position in SKYE in Q2 2024 and has held it in 4 quarters since. The position peaked at $49K in Q3 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Citigroup held 0 shares of Skye Bioscience worth $0 as of Q2 2026.
  • Citigroup left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #6327 holding.
  • Citigroup first reported a position in Skye Bioscience in Q2 2024 and has held it in 4 quarters since.
  • Citigroup's Skye Bioscience position peaked at $49K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.